"The voice for cancer physicians and their patients in Massachusetts."

FDA approves LIBTAYO® (cemiplimab-rwlc) in combination with platinum-based chemotherapy for non-small cell lung cancer

09 Nov 2022 1:30 PM | Katy Monaco (Administrator)

Food and Drug Administration approved LIBTAYO® (cemiplimab-rwlc)  (Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.  Read More

Please see additional Important Safety Information below and the full LIBTAYO Prescribing Information here or go to www.libtayohcp.com.

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software